Tech Company Financing Transactions
Armo Bio Sciences Funding Round
Armo Bio Sciences, operating out of Redwood City, secured $50 million in funding from Celgene, Clough Capital Partners and DAG Ventures.
Transaction Overview
Company Name
Announced On
2/10/2016
Transaction Type
Venture Equity
Amount
$50,000,000
Round
Series C
Investors
Proceeds Purpose
ARMO intends to use the proceeds from the financing to support the clinical development of its lead product candidate, AM0010 for the treatment of advanced solid tumors, and its pipeline of immunotherapies, including cytokines and an anti-Programmed Cell Death Protein (anti-PD-1) monoclonal antibody checkpoint inhibitor.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
575 Chesapeake Dr.
Redwood City, CA 94063
USA
Redwood City, CA 94063
USA
Phone
Undisclosed
Website
Email Address
Overview
ARMO Biosciences is a biotechnology company that develops immune modulatory biologic therapeutics.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Peter Van Vlasselaer
Chief Medical Officer
Joseph Leveque
Founder
Martin Oft
VP - Bus. Development
Scott Ogg
VP - Operations
Russell Kawahata
Browse more venture capital transactions:
Prev: 2/9/2016: PowerChord venture capital transaction
Next: 2/10/2016: CognitiveLogic venture capital transaction
Share this article
News on VC Transactions
Our team works diligently to document every notable VC transaction. VC transactions on this site come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs